Johnson & Johnson Retires Signature Script Logo After 130 Years, Adopts New Look to Reflect Focus on Healthcare

Johnson & Johnson is retiring its signature script logo after 130+ years. The logo was based on founder James Wood Johnson's signature.
The company is replacing the script with a more modern logo reflecting its focus on pharmaceuticals and medical devices.
The original logo was still seen on consumer products, now part of the spun-off Kenvue company.
J&J says the new logo recognizes its shift to a "pure play healthcare company."
The change comes as cursive writing fades and younger generations may not recognize the script logo.

go.com

Relevant topic timeline:

9/17/2023

Johnson & Johnson Offers Stability Despite Recent Underperformance

This article mentions Johnson & Johnson (NYSE:JNJ) as the stock being discussed. The author's recommendation is to buy this stock for portfolios with a lower risk tolerance. The author's core argument is that despite recent challenges, Johnson & Johnson is attractively valued and well-positioned for long-term growth and increasing shareholder returns. They highlight the company's AAA-rated balance sheet, its mix of growth and value, and its ability to protect investors from market turmoil. Key information and data include the underperformance of JNJ shares compared to the S&P 500, the uncertainty surrounding baby powder lawsuits, the company's future growth opportunities in MedTech and Pharmaceuticals, its commitment to R&D and innovation, and its shareholder distribution strategy, including a 3.0% dividend yield. The article also discusses the company's valuation and suggests that it may be trading below its fair value.

9/18/2023

Johnson & Johnson Spins Off Consumer Health, Lowers Guidance; Modest Growth Expected

Johnson & Johnson (JNJ) recently spun off its consumer healthcare products division in an effort to unlock value in its pharmaceutical business, but while this move may lead to slightly better growth, analysts are skeptical that it will deliver market-beating returns over the next decade. The author divested their JNJ investment due to underperformance and a low dividend growth rate, but still considers it a good choice for those seeking stability and safe income.

Topics

Posted 9/14/2023, 2:12:03 PM